Table 1.
Baseline Characteristics of Study Population
| Variable | All patients | Baseline infection only (n = 94) | Baseline and incident infection (n = 41) | Incident infection only (n = 268) | Never infected (n = 689) |
|---|---|---|---|---|---|
| Age, y | 48.8 (41.9−56.3) | 49.5 (41.9−54.7) | 47.1 (41.1−56.9) | 50.3 (42.6−58.8) | 48.3 (41.8−55.8) |
| Sex, male, n (%) | 685 (62.7) | 60 (63.8) | 26 (63.4) | 159 (59.3) | 440 (63.9) |
| Alcohol consumption, U/wk | 132 (84−210) | 125 (80−197) | 184 (96−249) | 120 (80−199) | 128 (84−210) |
| Prednisolone, n (%) | 547 (50) | 44 (47) | 20 (49) | 144 (54) | 339 (49) |
| Systolic blood pressure, mm Hg | 110 (102−120) | 112 (105−121) | 113 (100−126) | 110 (100−120) | 110 (102−120) |
| Diastolic blood pressure, mm Hg | 90 (60−74) | 69 (60−77) | 66 (58−77) | 65 (60−73) | 68 (60−75) |
| Pulse, beats/min | 90 (80−98) | 82 (88−98) | 95 (77−102) | 91 (80−100) | 89 (80−98) |
| Temperature, °C | 36.8 (36.5−37.1) | 36.8 (36.6−37.1) | 36.8 (36.4−37.3) | 36.8 (36.5−37.1) | 36.8 (36.5−37.1) |
| Hemoglobin, g/L | 107 (94−120) | 102 (90−114) | 100 (88−118) | 105 (94−120) | 108 (95−121) |
| Total white cell count, ×103per mm3 | 9.00 (6.23−12.6) | 9.90 (6.68−14.4) | 10.6 (7.05−16.1) | 10.1 (7.1−13.7) | 8.20 (6.00−11.9) |
| Neutrophils, ×103per mm3 | 6.2 (4.1−9.8) | 7.2 (4.2−11.6) | 6.9 (5.4−13.3) | 7.3 (4.9−11.0) | 5.7 (3.9−9.0) |
| International normalized ratio | 1.80 (1.56−2.09) | 1.91 (1.60−2.32) | 1.74 (1.58−2.00) | 1.82 (1.60−2.12) | 1.70 (1.51−2.00) |
| Albumin, g/L | 25 (21−29) | 26 (22−31) | 25 (18−31) | 24 (20−28) | 25 (21−29) |
| Bilirubin, mg/dL | 16.1 (10.1−24.4) | 14.7 (9.47−24.4) | 18.6 (9.6−25.7) | 16.7 (10.6−25.1) | 15.9 (9.90−24.0) |
| Alanine transaminase, IU/L | 43 (30−61) | 38 (27−51) | 39 (31−61) | 44 (28−64_ | 43 (31−62) |
| Aspartate transaminase, IU/L | 124 (87−169) | 125 (89−148) | 120 (90−164) | 122 (87−178) | 125 (87−171) |
| Sodium, mmol/L | 134 (130−136) | 134 (131−138) | 134 (130−137) | 133 (130−136) | 134 (130−137) |
| Urea, mmol/L | 3.3 (2.2−5.2) | 3.5 (2.4−6.7) | 4.3 (2.6−7.1) | 3.6 (2.2−5.4) | 3.1 (2.2−4.9) |
| Creatinine, mg/dL | 0.72 (0.60−0.97) | 0.72 (0.59−0.99) | 0.75 (0.62−1.03) | 0.76 (0.60−1.06) | 0.72 (0.60−0.92) |
| Discriminant functiona | 55.4 (43.1−73.7) | 62.1 (46.6−86.7) | 56.9 (47.0−68.4) | 60.6 (45.5−82.0) | 53.4 (42.1−69.8) |
| Model for End-Stage Liver Diseaseb | 23.4 (21.0−26.4) | 24.4 (21.7−28.6) | 24.3 (21.7−27.0) | 24.2 (21.4−28.1) | 22.9 (20.8−25.7) |
NOTE. Groupings are based on the entire study population, with subgroups of when the infection was diagnosed relative to the start of treatment. Baseline infection was defined as those that occurred between admission and the start of therapy. Incident infections were those that occurred after initiation of therapy. Data are presented median (interquartile range) unless otherwise indicated.
a
Discriminant function = 4.6 × (PTPatient − PTControl [seconds]) + bilirubin [mg/dL].
b
Model for End-Stage Liver Disease = 3.78 × ln[serum bilirubin (mg/dL)] + 11.2 × ln[INR] + 9.57 × ln[serum creatinine (mg/dL)] + 6.43.